The Global Psoriasis Drugs Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the Psoriasis Drugs market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.

Browse for Full Report at @ https://www.thebrainyinsights.com/report/psoriasis-drugs-market-12599

Key companies & product “values” (latest full-year reported)

• AbbVie — Skyrizi (risankizumab) $11.72B FY2024 net revenues.

• Johnson & Johnson (Janssen) — Stelara (ustekinumab) $10.4B FY2024 sales; Tremfya (guselkumab) $3.67B FY2024.

• Novartis — Cosentyx (secukinumab) $6.141B FY2024 net sales.

• Eli Lilly — Taltz (ixekizumab) $3.26B FY2024 (sum of quarterly Lilly disclosures: Q1 $604.1M, Q2 $824.7M, Q3 $879.6M, Q4 $952.0M).

• Amgen — Otezla (apremilast) FY2024: Q4 $624M; full-year –3% YoY (company did not publish a single FY figure in the release, but guided a 3% decline vs. 2023).

• UCB — Bimzelx (bimekizumab) €558M FY2024 net sales.

• Sun Pharma — Ilumya (tildrakizumab) $580M FY2024 (FY ended Mar-31-2024).

Benchmarks for total market size (directional): 2024 global psoriasis drugs market $20–31B depending on methodology; 2025–2030 CAGR typically ~8–11%. Use one series consistently in any model.

Recent development

• Wave of Stelara biosimilars in the U.S. (2025): Amgen’s Wezlana launched Jan-1-2025; multiple others (Selarsdi, Pyzchiva, Yesintek, Otulfi, Steqeyma, Imuldosa) rolled out through 2025, introducing steep list-price competition. Expect pressure on Stelara share/price and payer dynamics.

• Label/indication expansions: Bimzelx (bimekizumab) gained U.S. approvals for PsA & axial spondyloarthritis in 2024, broadening its psoriasis-anchored franchise. 

• Oral TYK2 momentum: BMS Sotyktu (deucravacitinib) posted positive Ph3 PsA topline (2024), supporting uptake beyond plaque psoriasis. 

Drivers

• Shift to targeted biologics (IL-23/IL-17) and TYK2 oral agents delivering deep skin clearance and convenient dosing.

• High disease prevalence & under-treatment, plus earlier biologic use in moderate disease. (See market reports for prevalence-linked growth.)

• New indications (PsA, axSpA) that expand eligible populations for IL-17/23 drugs.

Restraints

• Intense payer management/price pressure in the U.S., amplified by Stelara biosimilars and PBM strategies (dual high/low WAC, private-label channels). 

• Biosimilar erosion (ustekinumab 2025; adalimumab precedent) limiting revenue growth for originators. 

• Safety/monitoring burdens for systemic immunomodulators and step-therapy hurdles. (Reflected across payer/biosimilar briefs.) 

Regional segmentation analysis (quick read)

• North America: Largest revenue pool; rapid biosimilar uptake will reshape mix/pricing.

• Europe: Strong biologic penetration; tendering & HTA keep prices lower than U.S. (market outlook sources).

• Asia-Pacific: Fastest growth via access expansion (notably China) and rising diagnosis rates; still lower biologic penetration vs. West. (Market model consensus.) 

Emerging trends

• TYK2 class build-out (Sotyktu) as preferred oral option vs. PDE4. 

• Next-gen topicals (roflumilast cream/foam, tapinarof) creating biologic-sparing options & combo pathways. 

• Treat-to-target (PASI90/100) normalizing, favoring IL-23 leads (Skyrizi, Tremfya). 

Top use cases

• Moderate–severe plaque psoriasis (systemics/biologics).

• Psoriatic arthritis (shared IL-17/23, TNF inhibitors; oral TYK2 in development). 

• Sensitive-area psoriasis / intertriginous disease (PDE4 topical roflumilast).

Major challenges

• Access & affordability: formulary exclusions, step edits, patient OOP costs despite copay support. 

• Biosimilar substitution dynamics (pharmacy-level switching; private-label channels). 

• Long-term safety vigilance for immunomodulators; vaccine/latent infection workflows (class effect context).

Attractive opportunities

• Capture share in the ustekinumab LOE window (2025+) via competitive pricing, service, and interchangeability positioning.

• Expand orals (TYK2) for patients avoiding injections; combine with modern topicals for step-up care. 

• APAC market access: local real-world evidence & NRDL/tender strategies (market growth forecasts). 

Key factors of market expansion

• Clinical differentiation (PASI90/100 rates, durability, dosing convenience) of IL-23/IL-17 agents.

• Broader indications (PsA/axSpA) increasing treatable population. 

• Policy & pricing shifts from biosimilars unlocking volume but pressuring ASPs—net neutral to positive for total treated patients.

If you want, I can drop this into a one-page slide or a table you can paste into your report.